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Abstract 
Introduction. The role and selection of antithrombotic therapy to improve limb 
outcomes in chronic lower extremity artery disease (LEAD) is still debated. We 
conducted a meta-analysis to examine the efficacy and safety of anti-thrombotic and 
more intense antithrombotic therapy on limb outcomes and limb salvage in patients 
with chronic LEAD. 
Methods. Study inclusion criteria were: enrollment of patients with LEAD, randomized 
allocation to more vs. less intense antithrombotic therapy [more vs. less intense single 
antiplatelet therapy (SAPT); dual antiplatelet therapy (DAPT) vs. SAPT; dual 
antithrombotic therapy vs. SAPT or oral anticoagulant]; enrolment of >200 patients; 
reporting of at least one of following outcomes: limb amputation or revascularization. 
Seven randomized studies enrolling 30’447 patients were included.  
Results. Over a median follow-up of 24 months, more vs. less intense antithrombotic 
therapy or placebo significantly reduced the risk of limb revascularization (relative risk 
[RR]: 0.89; 95% confidence interval [CI]: 0.83 – 0.94) and limb amputation (RR: 0.63, 
95% confidence interval [CI]: 0.46-0.86), as well as stroke (RR: 0.82, 95% CI: 0.70-
0.97). There was no statistically significant effect on the risk of myocardial infarction 
(RR: 0.98, 95% CI: 0.87-1.11), all-cause (RR: 0.93, 95% CI: 0.86-1.01) and 
cardiovascular death (RR: 0.97, 95% CI: 0.86-1.08). Risk of major bleeding increased 
(RR: 1.23, 95% CI: 1.04-1.44). 
Conclusion: In patients with LEAD, more intense antithrombotic therapy reduces risk 
of limb amputation and revascularization as well as stroke, with an increase in the risk 
of bleeding events. 
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Abbreviations 
ABI   Ankle-brachial index 
ADEP   Atherosclerotic Disease Evolution by Picotamide 
BID   Twice a day 
CAD   Coronary artery disease 
CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic 
Stabilization, Management, and Avoidance 
CI Confidence intervals 
COMPASS  Cardiovascular Outcomes for People Using Anticoagulation 
Strategies 
CV   Cardiovascular 
DAPT Dual antiplatelet therapy 
DAVID  Drug evaluation in Atherosclerotic Vascular disease In Diabetics 
EUCLID  Examining Use of Ticagrelor in Peripheral Artery Disease 
GRADE Grading of recommendations assessment, Development and 
Evaluation 
GUSTO Global Utilization of Streptokinase and Tissue Plasminogen 
Activator for Occluded Coronary Arteries 
HYLD Hyperlipidemia 
HYPT Hypertension 
ISTH International Society of Thrombosis and Hemostasis 
LDL Low-density lipoprotein 
LEAD Lower extremity artery disease 
LLA Lipid lowering agents 
MACCE  Major adverse cardio- and cerebrovascular events 
MALE Major adverse limb events 
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MI Myocardial infarction 
QD Once a day 
PEGASUS-TIMI 54 Prevention of Cardiovascular Events in Patients with Prior Heart 
Attack Using Ticagrelor Compared to Placebo on a Background of 
Aspirin–Thrombolysis in Myocardial Infarction 54 
POPADAD  prevention of progression of arterial disease and diabetes 
RR Relative risk 
SAPT Single antiplatelet therapy 
STIMS  Swedish Ticlopidine Multicentre Study  
TIMI Thrombolysis in myocardial infarction 
TID three times a day 
TRA 2P–TIMI 50 Thrombin Receptor Antagonist in Secondary Prevention of 
Atherothrombotic Ischemic Events (TRA 2P) – Thrombolysis in 
Myocardial Infarction (TIMI) 50 
TRACER Thrombin Receptor Antagonist for Clinical Event Reduction in 
Acute Coronary Syndrome 
 
 
  
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz036/5544981 by Aalborg U
niversity Library user on 15 August 2019
 7 
Introduction 
Lower extremity peripheral artery disease (LEAD) is a disabling disease which 
affects 40 million people in Europe and 202 million people globally.1 It is a 
manifestation of systemic atherosclerosis and is associated with an increased risk of 
cardiovascular (CV)- and cerebrovascular disease. In Western Europe, annual 
mortality rate is 3.5 per 100’000 individuals.1 The rate of lower extremity amputation, a 
major complication of LEAD, ranges between 120 and 500 per million and is 
associated with significant morbidity, mortality and health-care costs.1-3  
Arterial thrombosis following atherosclerotic plaque rupture, and subsequent 
activation of platelets and coagulation,3, 4 is a key event in the pathogenesis of acute 
and chronic limb threatening ischemia, potentially leading to the clinical cascade which 
results in need for endovascular or surgical revascularization or, when this is 
unsuccessful, to limb amputation.5 Current guidelines of the European Society of 
Cardiology/ European Society of Vascular Surgery guidelines (ESC/ESVS) and 
American Heart Association/American College of Cardiology (AHA/ACC) recommend 
the use of single antiplatelet therapy (SAPT) to reduce the risk of myocardial infarction 
(MI), stroke and vascular death in patients with symptomatic LEAD (IA 
recommendation).1, 5 However, there is no recommendation for antithrombotic therapy 
to reduce major adverse limb events (MALE) in LEAD patients. Indeed previous trials 
in LEAD populations were undertaken and powered only for major adverse CV or 
cerebrovascular events (MACE).6 Little attention was paid to limb outcomes, a limited 
number of MALE were reported, and most studies were underpowered to detect the 
effect of antithrombotic therapies on limb outcomes. The role of more intense 
antithrombotic therapy in preventing MALE in LEAD patients is currently of major 
interest, especially in view of the recent Prevention of Cardiovascular Events in 
Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a 
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Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) 
and Cardiovascular Outcomes for People Using Anticoagulation Strategies 
(COMPASS) trials which support a more intense antithrombotic approach over SAPT.7, 
8  
The aim of this study was to evaluate the efficacy and safety of antithrombotic 
and, especially, more intense antithrombotic therapy in reducing need for acute limb 
revascularization and amputation in patients with chronic LEAD by a meta-analysis of 
randomized controlled trials.   
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Methods 
Data sources and search strategy 
The meta-analysis was designed according to PRISMA (Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses) statement. PubMed and ISI Web of 
Science databases were searched for articles published until January 2019 combining 
the following terms [(“peripheral artery disease” OR “peripheral arterial disease” OR 
“intermittent claudication”) AND (“randomized” OR “randomised”)]. No language 
restrictions were applied. 
 
Study selection 
Study inclusion criteria were: enrollment of patients with LEAD (studies not 
reporting separately outcomes for patients with LEAD and carotid artery disease were 
not considered) defined as in Supplemental Material Table 1, randomized allocation to 
more vs. less intense chronic antithrombotic therapy [more vs. less intense SAPT; dual 
antiplatelet therapy (DAPT) vs. SAPT; dual antithrombotic therapy vs. SAPT or oral 
anticoagulant]; enrolment of more than 200 patients; reporting of at least one of 
following outcomes: limb amputation or lower limb revascularization. Studies 
assessing the use of antithrombotic drugs following an acute limb intervention 
(percutaneous or surgical revascularization) were not considered eligible. 
 
Data extraction and quality assessment 
Articles were screened for fulfillment of inclusion criteria by two independent 
reviewers (GS, DDA). The reviewers compared selected trials and discrepancies were 
resolved by agreement. Corresponding authors were asked to provide full-text articles, 
if they were not publicly available. From each study, information about methods, year 
of publication, number of patients in treatment and control arms, duration of follow-up, 
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age, gender, data on prevalence of hypertension, diabetes, coronary artery disease 
(CAD), hyperlipidemia, smoking, use of aspirin and lipid-lowering agents were 
collected and entered into STATA (version 14.2, StataCorps, College Station, Texas) 
by one author (DDA) and checked by another author (GS). The outcomes abstracted 
were limb amputation and lower limb revascularization, major bleeding, all-cause 
death, CV death, MI and stroke. The definition of amputation and bleeding for the 
different trials included is reported in Supplemental Material Table 2. 
The GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) method was used to summarize the findings and score the overall quality 
of evidence. 
 
Data synthesis and analysis 
Relative Risks (RR) of the effect of randomized treatments were calculated 
using the metan routine (STATA Statacorp, version 14.2) to account the probability of 
events occurring in treatment group versus control group. Relative risks (RRs) and 
95% Confidence Intervals (CIs) for each outcome were calculated separately for each 
trial, with grouped data using the intention-to-treat principle (when applicable). Overall 
estimates of effect were calculated with a fixed effect model (Mantel-Haenszel method) 
or a random-effects (DerSimonian and Laird) model in presence of non-explainable 
significant heterogeneity.  
The assumption of homogeneity between the treatment effects in different trials 
was tested by Q statistic and further quantified by I2 statistic. A significant heterogeneity 
was defined by a p<0.10 at Q statistic; I2 ranging from 0% to 40% might indicate not 
important heterogeneity, from 30% to 60% might represent moderate heterogeneity, 
from 50% to 90% might indicate substantial heterogeneity and from 75% to 100% 
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might represent considerable heterogeneity. The significance level for all outcome and 
heterogeneity analyses was set at p<0.05. 
 
Sensitivity analysis 
To assess the consistency of outcome meta-analysis results, the influence of 
each individual study on the summary effect estimate was assessed by the 1-study 
removed sensitivity analysis using the “metaninf” command (STATA). 
To explore the influence of potential effect modifiers on outcomes, random-
effects meta-regression analyses weighted for the inverse of studies’ variances were 
performed with the “metareg” command (STATA) to test demographic characteristics 
of the study population, CV risk factors, and concomitant medications. 
 
Publication bias 
To evaluate potential publication bias, Peter’s test was performed. The 
significance level for the publication bias analysis was set at p<0.05. 
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Results 
Characteristics of included trials  
The characteristics of included trials are reported in Table 1 and Supplemental 
Material Table 1. Of 6’273 manuscripts identified in the initial search, 4’383 were 
retrieved for more detailed evaluation after the removal of duplicates. Thereafter, 7 
randomized controlled trials were finally included, which enrolled 30’447 patients, of 
which 16’445 randomized to a more intense vs. 14’002 randomized to a less intense 
antithrombotic therapy regimen or placebo. One trial, COMPASS, evaluated a dual 
anticoagulant-antiplatelet approach (rivaroxaban + aspirin vs. rivaroxaban or aspirin 
alone), whereas 6 trials (24’056 patients) compared different antiplatelet therapy 
approaches. Median age was 66 (range 64 – 68) years, 32% were women. Median 
follow-up was 24 (range 16.5 – 36) months. 
 
Outcome analysis 
 Limb amputation and limb revascularization occurred in 0.8% and 9.9% of 
patients randomized to more intense vs. 1.3% and 11.9% of those enrolled to less 
intense antithrombotic therapy, respectively. Thus, more intense antithrombotic 
treatment reduced the risk of limb amputation by 37% (RR: 0.63; 95% CI: 0.46 – 0.86) 
and the risk of limb revascularization by 11% (RR: 0.89; 95% CI: 0.83 – 0.94) with no 
statistical heterogeneity (pQ = 0.96 and 0.37; I2 = 0.0% and 8.1%, respectively) (Figure 
1). 
 MI and stroke occurred in 4.5% and 1.6% of patients allocated to a more intense 
antithrombotic treatment vs. 4.6% and 2.1% of those randomized to a less intense 
approach. Thus, although the treatment did not significantly reduce the risk of 
myocardial infarction (RR: 0.98; 95% CI: 0.87 – 1.11), a significant 18% reduction of 
risk of stroke was observed in patients treated with a more vs. less intense 
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antithrombotic approach (RR: 0.82; 95% CI: 0.70 – 0.97), with no statistical 
heterogeneity (pQ = 0.14 and 0.47; I2 = 45.6% and 0.0%, respectively) (Figure 2). 
 As many as 8.4% and 4.9% of patients receiving a more intense treatment vs. 
9.0% and 5.0% of those allocated to a less intense antithrombotic approach died from 
any or CV cause, respectively. Thus, the 7%  reduction in risk of all-cause death (RR: 
0.93; 95% CI: 0.86 – 1.01) induced by a more vs. less intense antithrombotic therapy 
did not reach statistical significance, and no reduction in risk of CV death was observed 
(RR: 0.97; 95% CI: 0.86 – 1.08), with no statistically significant heterogeneity for both 
outcomes (pQ = 0.13 and 0.11; I2 = 44.4% and 46.6%, respectively)(Figure 3). 
 The occurrence of major bleeding was observed in 2.0% of patients treated with 
more intense vs. 1.6% of those receiving less intense anti-thrombotic therapy. Thus, a 
more intense anti-thrombotic treatment regimen was significantly associated with a 
23% increase in risk of major bleeding (RR: 1.23; 95% CI: 1.04 – 1.44), with no 
statistically significant heterogeneity (pQ = 0.12; I2 = 40.5%)(Figure 4). 
 
Methodology quality 
The assessment of the overall quality of evidence according to the GRADE 
method is shown in Supplemental Material Table 3. Most reported outcomes were 
scored with a high level of evidence. We downgraded limb amputation with one point 
due to moderate risk of imprecision; the total number of events was small which lead 
to a larger confidence interval compared to the other outcomes. We also downgraded 
CV death and all-cause death with one point due to publication bias. No publication 
bias was reported for any of the other outcomes (p>0.10 at Peters’ test). 
 
Sensitivity analysis 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz036/5544981 by Aalborg U
niversity Library user on 15 August 2019
 14 
 One-study removed analysis confirmed mostly all the results (Supplemental 
Figures 1-7). After the removal of the Examining Use of Ticagrelor in Peripheral Artery 
Disease (EUCLID) and PEGASUS-TIMI 54 trials, the reduction in risk of stroke induced 
by a more intense antithrombotic treatment only approximated statistical significance. 
Additionally, after the removal of EUCLID a more vs. less intense antithrombotic 
treatment significantly removed the risk of all-cause and CV death. After the removal 
of the COMPASS trial, treated and control patients showed similar risk of major 
bleeding. 
Meta-regression analyses showed a potential role for age as effect modifier for 
risk of major bleeding (p=0.049) (Supplemental Material Table 4). 
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Discussion 
In this meta-analysis we found that a more intense antithrombotic therapy, 
including a more vs. less intense SAPT, DAPT vs. SAPT or a combination of 
antiplatelet and anticoagulant therapy, significantly reduced the risk of limb 
revascularization compared to a less intense control group by 11%, and importantly, 
limb amputation, by 37%, over a median follow-up of 24 months. Stroke was also 
statistically significantly lower in patients treated with a more intense antithrombotic 
approach. The 7% reduction in risk of all-cause death observed in patients treated with 
more vs. less intense antithrombotic treatment did not reach statistically significance. 
The more intense therapies (moving from single antiplatelet to dual antiplatelet to 
antiplatelet-anticoagulant combination) were more effective, but also caused more 
bleeding. The data regarding MALE (particularly limb salvage) are compelling and 
provide evidence on the limb-specific benefits of antithrombotic therapy which should 
be considered in clinical patient management. 
 
Current guideline recommendations 
The current ESC/ESVS guidelines recommend in chronic LEAD patients (i.e. 
not following revascularization) 1) no antiplatelet therapy if asymptomatic (III A 
recommendation); and 2) long-term SAPT, preferentially the more efficient P2Y12 
receptor antagonist clopidogrel over aspirin, if symptomatic (I A).1 Yet, anticoagulation 
is only recommended in patients with co-morbidities that require anticoagulant therapy 
independent of the LEAD.1 The guidelines of the AHA/ACC recommend antiplatelet 
therapy also in asymptomatic LEAD patients with an ankle brachial index ≤ 0.9 (IIa C 
recommendation), and they suggest SAPT with aspirin or clopidogrel without 
preferences in symptomatic LEAD patients (I A recommendation).5 Furthermore, they 
add that the overall benefit of vorapaxar in addition to antiplatelet therapy in 
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symptomatic LEAD patients is uncertain (IIb B recommendation), and they recommend 
against the use of anticoagulants (III A recommendation).5 This meta-analysis does 
not provide enough granularity to specifically address asymptomatic versus 
symptomatic patients. 
 
Platelet inhibition in LEAD  
Platelets play a pivotal role in arterial thrombosis,3 and thus, stronger inhibition 
of platelet aggregation seems reasonable in order to prevent thrombus formation and 
its consequences on clinical outcome. In chronic (not requiring revascularization) 
patients, SAPT vs. placebo reduced need for acute limb interventions.9, 10 However, 
the newer P2Y12 receptor antagonist ticagrelor, which exhibits somewhat greater 
inhibition of adenosine diphosphate-induced platelet aggregation than clopidogrel,11 
was not more effective when evaluated in chronic LEAD patients.12-15 Indeed, the 
EUCLID trial compared these single antiplatelet drug regimens - ticagrelor vs. 
clopidogrel - as antiplatelet mono-therapy in 13’885 patients with symptomatic LEAD 
and found no differences in MACE or hospitalizations for MALE or major bleeding 
events.12 In contrast, a post-hoc analysis of PEGASUS-TIMI 54, which included 1’143 
LEAD patients with a prior MI, showed that DAPT, using ticagrelor (60 mg or 90 mg 
twice daily) plus aspirin (pooled analysis), compared with aspirin alone, did reduce 
MACE and MALE without increasing major bleeding events.13 The reduction in MACE 
and more importantly, the decrease in overall mortality, were driven by low-dose 
ticagrelor, whereas the reduction in MALE was driven by ticagrelor 90 mg twice daily.13 
These results are in line with the overall findings in this meta-analysis, that increasing 
antithrombotic and, particularly, more intense antithrombotic therapy is beneficial in 
reducing limb revascularization and limb amputation, and supported by a previous 
meta-analysis showing greater benefit in terms of reduction of major amputations 
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following leg revascularization in patients receiving a more intense antiplatelet 
approach (i.e. DAPT with clopidogrel plus aspirin vs. SAPT), but also a significantly 
increased risk of bleeding16. We also showed that a more intense antithrombotic 
approach was associated with increased risk of bleeding, but it was mostly driven by 
the inclusion of the COMPASS trial testing the direct factor Xa inhibitor rivaroxaban +/- 
aspirin vs. aspirin alone. Indeed, after the removal of COMPASS trial, a more vs. less 
intense antiplatelet therapy still reduced the risk of limb revascularization without 
impacting on the risk of major bleeding. 
 
Anticoagulation in LEAD  
In addition to platelets, the coagulation cascade is crucial for arterial thrombus 
formation. It not only enhances platelet activation via thrombin but also causes cross-
linkage of platelets by fibrin leading to stable clot formation.6 Indeed, anticoagulation 
with vitamin-K antagonists has been previously shown to reduce the risk for thrombotic 
events but to significantly increase the bleeding risk in CAD patients.15 In the 
COMPASS study, a dual anti-thrombotic regimen of low-dose rivaroxaban (2.5 mg 
twice a day) plus aspirin, compared with aspirin alone, reduced the risk for stroke, MI 
and CV death in 27’395 patients with stable CAD disease, LEAD or carotid artery 
disease.7 In a post-hoc analysis of the COMPASS trial including the 6’391 LEAD 
patients, low-dose rivaroxaban plus aspirin, compared with aspirin alone, reduced 
MALE as well as major amputation but increased major bleeding events.14 
Rivaroxaban alone (5 mg twice daily), compared with aspirin, did not reduce MALE or 
major amputations but did increase major bleeding events.14 The benefits of a more 
intense antithrombotic approach in terms of reduction of major disabling clinical 
outcome events such as MALE (particularly limb salvage) and MACE outcomes may 
outweigh the increased risk of bleeding, with a net clinical benefit in LEAD patients. 
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Strengths and limitations of the study  
Strength of our meta-analysis is the large sample size, which led to a powered 
analysis of outcomes such as limb amputation and revascularization. Limitations 
include (i) the fact that the analyses were based on aggregate trial-level data and not 
on patient-level data, which prevented time-to-event analyses and investigation of 
important subgroups of LEAD patients (i.e. symptomatic or asymptomatic LEAD). (ii) 
We pooled trials testing different pharmacological treatments (i.e. single antiplatelet 
therapy, dual antiplatelet therapy, combination of anticoagulant and antiplatelets), 
which thus represent different mechanisms of action, and may have different effects 
on outcomes. Moreover, the included trials investigated different patient populations, 
e.g. primarily LEAD patients in EUCLID vs. patients with CAD/MI and LEAD in 
PEGASUS, which may have led to different effects. Additionally, different levels of 
antithrombotic treatment intensity were tested in the different trials (less vs more 
intense SAPT, DAPT, dual antithrombotic treatment), which makes it difficult for clinical 
specific clinical recommendations (iii) LEAD was differently defined across the studies 
included in our meta-analysis and there were also some differences in outcome 
definitions, and thus the effects of the treatments might have varied according to the 
definition used. However, the lack of significant heterogeneity for all the outcome 
analyses suggests consistency of treatment effect across the trials, which is also 
confirmed by the one-study removed meta-analysis. (iv) Finally, patients’ 
characteristics varied across the trials, but, except for a potential role for age on risk of 
major bleeding, we excluded the effect of any other known baseline characteristic on 
our results by a meta-regression analysis.  
 
Conclusions  
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An antithrombotic and more intense antithrombotic therapeutic regimen reduces 
limb amputation and revascularization in chronic LEAD patients, as well as risk of 
stroke, but increases the risk of bleeding. These findings may foster changes in clinical 
practice, while encouraging future randomized trials powered specifically on MALE 
outcomes in chronic LEAD patients. 
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FIGURES LEGEND 
 
Figure 1. Risk of limb amputation and limb revascularization. Gray squares 
represent relative risks (RRs) in trials. The 95% confidence intervals (CIs) for individual 
trials are denoted by lines and those for the pooled RRs by open diamonds. Meta-
analysis is performed by fixed effects model. DAPT = dual antiplatelet therapy, 
CHARISMA = Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, 
Management, and Avoidance, COMPASS = Cardiovascular Outcomes for People 
Using Anticoagulation Strategies, DAVID = Drug evaluation in Atherosclerotic Vascular 
disease In Diabetics, OAC = oral anticoagulant, PEGASUS-TIMI 54 = Prevention of 
Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared 
to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54, 
SAPT = single antiplatelet therapy, TRACER = Thrombin Receptor Antagonist for 
Clinical Event Reduction in Acute Coronary Syndrome.  
 
Figure 2. Risk of myocardial infarction and stroke. EUCLID = Examining Use of 
Ticagrelor in Peripheral Artery Disease, TRA 2P–TIMI 50 = Thrombin Receptor 
Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2P) – 
Thrombolysis in Myocardial Infarction (TIMI) 50. Explanation of the graph and other 
abbreviations as in Figure 1. 
 
Figure 3. Risk of all-cause and cardiovascular death. Explanation of the graph and 
other abbreviations as in Figure 1 and 2. 
 
Figure 4. Risk of major bleeding. Explanation of the graph and other abbreviations 
as in Figure 1 and 2. 
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Table 1. Baseline characteristics of studies included in the meta-analysis. 
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CHARISMA17, 18 Clopidogrel plus 
low-dose aspirin 
vs. placebo plus 
low-dose aspirin  
26 1545 1551 66 30 25 9 51 85* 36 70 72 85 100 
COMPASS7, 14 Rivaroxaban (2·5 
mg BID) plus 
aspirin; 
Rivaroxaban BID 
(5 mg with aspirin 
placebo QD);  
Aspirin OD (100 
mg and 
rivaroxaban 
placebo BID) 
21 4268 2123 68 28 65 - 32 75* 45 - 79 82 100 
DAVID19 Picotamide vs. 
aspirin  
24 603 606 64 27 19 10 - 71* 100 38 57 15 50 
EUCLID12 Ticagrelor vs 
clopidogrel  
30 6930 6955 66 28 29 8 57 78* 39 76 78 73 67 
PEGASUS-TIMI 
5413, 20 
Ticagrelor vs 
placebo on a 
background of 
aspirin 
33 739 404 66 22 100 3 34 30# 42 81 85 93 100 
TRA 2P-TIMI 
5010, 21 
Vorapaxar vs 
placebo  
36 1892 1895 66 29 57 14 62 31# 36 87 83 82 88 
TRACER22, 23 Vorapaxar vs 
placebo  
16.5 468 468 66 26 44 10 - 77* 46 78 85 87 96 
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*Current or former smoker, #Current smoker. CAD = coronary artery disease, HYLD = hyperlipidemia, HYPT = hypertension, LLA = lipid 
lowering agents. Other abbreviations as in Figure 1 and 2. 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
D
ow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz036/5544981 by Aalborg U
niversity Library user on 15 August 2019
Figure 1 Dow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz036/5544981 by Aalborg U
niversity Library user on 15 August 2019
Figure 2 Dow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz036/5544981 by Aalborg U
niversity Library user on 15 August 2019
Figure 3 Dow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz036/5544981 by Aalborg U
niversity Library user on 15 August 2019
Figure 4 Dow
nloaded from
 https://academ
ic.oup.com
/ehjcvp/advance-article-abstract/doi/10.1093/ehjcvp/pvz036/5544981 by Aalborg U
niversity Library user on 15 August 2019
